Key Stats for PFE Stock
- Past week performance: Consolidating
- 52-week range: $24 to $29
- Valuation model target price: $28
- Implied upside: 2.8% over 2.3 years
Build Pfizer’s forecast into TIKR’s free Valuation Model (It’s free) >>>
A Quiet Stock Hiding a Loud Quarter
Pfizer (PFE) barely moved this week. That quiet is the real story. Shares sit near $28, only a hair off where they started, even though the company just delivered one of its stronger quarters in years. Pfizer beat Q2 estimates with adjusted earnings per share of $0.77 and raised its full-year revenue guidance to $60.5 billion to $62.5 billion. Non-COVID products, the part of the business investors actually care about now, grew 18% operationally.
The market’s muted reaction says something important. Pfizer’s COVID-era windfall is gone, and investors have spent two years waiting to see if the rest of the business can carry the stock. This quarter, it did. Launched and acquired medicines, including Padcev and drugs from the Seagen and Metsera deals, drove the growth. Pfizer also expanded its cost-cutting target to $6.7 billion through 2029, on top of $3 billion in manufacturing savings, so margins have room to widen even as COVID revenue fades.
CEO Albert Bourla struck a confident tone on the earnings call. He framed the results as proof that the strategy is working. “We had another strong quarter of execution, driving continued strategic progress,” he said. That confidence matters because Pfizer still carries the overhang of patent expirations later this decade. Bourla needs the pipeline and cost cuts to convince investors the growth is durable, not a one-quarter blip.
There’s a regulatory backdrop too. Pfizer’s XFG-adapted Comirnaty vaccine won FDA approval for the 2026 to 2027 season, and the company remains part of the White House’s drug-pricing agreements. If Pfizer stock stays this quiet, it will likely be because the market wants to see the trend hold for more than one quarter.
See analysts’ growth forecasts and price targets for PFE (It’s free) >>>
Is PFE Stock Undervalued?
Under valuation model assumptions realized through 12/31/28, the stock is modeled using:
- Revenue Growth (CAGR): (4.2%)
- Operating Margins: 35.0%
- Exit P/E Multiple: 9.9x
Based on these inputs, the model estimates a $28 target price, implying a 2.8% total return from the current share price and a 1.2% annualized return over the next 2.3 years.
That 1.2% annualized figure tells the real story. Pfizer isn’t priced like a broken company, but it isn’t priced like a growing one either. The market has settled on a stock that trades near 9.9x forward earnings, well below its historical range, because the projected top line actually shrinks slightly under conservative assumptions. Investors are betting on the dividend, not the growth, as the reason to own the stock.
Margins are the bright spot. A 35% operating margin assumption reflects Pfizer’s aggressive cost program, and management already banked savings ahead of schedule. But margin expansion can only do so much when revenue is flat to down. Pfizer needs its newer oncology and obesity programs to offset the erosion from COVID products and upcoming patent cliffs, and that transition is still in progress.
Pfizer traded above 15x earnings for most of the past decade before the pandemic-era boom and bust reset expectations. A 9.9x exit multiple isn’t a bet on a re-rating so much as an acknowledgment that the multiple already compressed and might just hold steady. That’s a value stock, not a value trap, only if the dividend stays intact and the pipeline delivers.
Benchmark Pfizer against Bristol Myers Squibb (Free with TIKR) >>>
Where Pfizer Stacks Up Against Big Pharma
Pfizer isn’t the only large-cap drugmaker navigating a post-COVID reset, and the comparison against its closest peers explains why the stock trades where it does. Merck (MRK) posted stronger one-year returns and faster near-term revenue growth near 4.6%, but the market prices in real risk. Keytruda alone drives roughly half of Merck’s pharma revenue, and its patent cliff looms in 2028. Merck’s forward P/E sits closer to 23x, more than double Pfizer’s multiple, largely because investors still expect growth there.
Bristol Myers Squibb (BMY) is the more direct comparison. BMY trades at a forward P/E near 9x to 10x, similar to Pfizer, and carries a dividend yield around 3.8% to 4.0%, well below Pfizer’s roughly 6.3%. Bristol guided 2026 revenue to $46.0 billion to $47.5 billion, reflecting a 12% to 16% decline in its legacy portfolio that its newer Growth Portfolio, up 12% year over year, is working to offset. Both stocks face the same dynamic as Pfizer: aging blockbusters fading while newer drugs try to fill the gap.
Pfizer’s edge is scale and diversification. Its oncology franchise, built through the Seagen acquisition, and its expanding presence in obesity through the Metsera deal give it more shots on goal than Bristol’s narrower pipeline. Merck’s growth looks better on paper, but its concentration risk in a single drug is arguably more dangerous than Pfizer’s broader, slower-growing base. None of the three stocks screens as expensive right now, and that reflects industry-wide caution as much as company-specific weakness.
Follow the August 4 earnings report for non-COVID growth, guidance, and the Metsera integration >>>
What’s Driving PFE Stock Going Forward?
The most important catalyst is the 2028 patent cliff, when key drugs lose exclusivity and Pfizer needs its newer launches already scaled. Management says the cost-savings program and oncology pipeline should support high single-digit growth once that transition passes, but the next two years are the proving ground. Every quarter that non-COVID revenue keeps growing 15% to 18% makes that outcome look more achievable.
Obesity is the wildcard. Pfizer’s Metsera acquisition, secured after a bidding war with Novo Nordisk, gives the company an entry into the GLP-1 market that Eli Lilly and Novo currently dominate. Early trial data for Pfizer’s ultra-long-acting injectable GLP-1 showed promising weight-loss results, and a strong Phase 3 readout could shift how investors value the pipeline.
Regulatory and pricing developments remain a swing factor too. Pfizer is part of the administration’s broader drug-pricing framework, and how those agreements evolve will shape U.S. pricing power for years. Vaccine demand is another moving piece, because COVID revenue now depends more on seasonal uptake than pandemic-level urgency, and low infection rates already pressured Paxlovid sales this year.
If Pfizer’s pipeline keeps converting and the cost program holds, the stock’s low multiple could eventually expand. Until then, the dividend and the discount are doing the heavy lifting.
Chart Pfizer’s pipeline catalysts (Free with TIKR) >>>
Should You Invest in Pfizer?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up PFE, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track PFE alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze PFE stock on TIKR Free→
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
